Experts warn that the Trump administration’s new $100,000 fee for H-1B visa applications could worsen healthcare’s workforce crisis, especially in rural areas, by making it prohibitively expensive for hospitals to hire international clinicians. Critics are also worried that the change could slow the pace of healthcare innovation by discouraging foreign workers from contributing to the tech and research sectors in the U.S.| MedCity News
The government shutdown is drawing backlash from healthcare leaders over its potential to disrupt ACA subsidies, Medicare telehealth access and programs like SNAP.| MedCity News
MedCity News Editor in Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch, also discussed whether bitcoin would play a greater role in healthcare deals and the Trump administration's mixed messages on autism and Tylenol.| MedCity News
Newly launched Pfizer drugs will be priced at parity to prices in comparable developed nations, according to the most-favored nation pricing agreement. But industry observers note that big pharma companies are also raising some prices overseas as part of a strategy to protect U.S. revenue.| MedCity News
Leaders from the VA and the ONC discussed how the future of U.S. healthcare will rely on both technology and creative problem-solving during a panel at DiMe’s Healthcare 2030 Summit.| MedCity News
A federal judge in Texas recently ruled on medical debt reporting — here's what the ruling means for providers and for the millions of Americans who currently have or might one day have medical debt.| MedCity News
As the FDA’s top biologics official, Peter Marks oversaw regulation of cell and gene therapies. The departure of Marks and mass layoffs throughout the FDA raise concerns about the agency’s ability to review and potentially approve such treatments.| MedCity News
The Trump administration recently cancelled billions of dollars in funding to the NIH. Healthcare experts say the funding cuts will delay the pace of medical research in the U.S. — which will not only hamper the commercialization of life-saving treatments, but could also hurt the country’s position as a global leader in healthcare and technology.| MedCity News
